Stay updated with breaking news from Charlesm Baum. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Guggenheim Capital LLC reduced its stake in Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Rating) by 23.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 24,340 shares of the biotechnology company’s stock after selling 7,570 shares during the quarter. Guggenheim Capital LLC’s holdings in Mirati […]
Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Rating) – Stock analysts at B. Riley decreased their Q1 2023 earnings estimates for Mirati Therapeutics in a report released on Wednesday, December 7th. B. Riley analyst K. Patel now forecasts that the biotechnology company will earn ($3.32) per share for the quarter, down from their prior estimate of […]
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of Alan Sandler, M.D., to...
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of Alan Sandler, M.D., to...
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform...